In a couple of earlier postings, I discussed how the German company managing the patent portfolio of the Deutsche Bank IP funds has gone bankrupt. While the funds are still operating, this raise the question as to whether this model of acquiring patents for further development is viable. The idea is to take technologies that are not yet ready for commercialization and finish the job. This is in contrast to the model of acquiring patents to already developed and being utilized technologies -- to gain the licensing revenues and legal assertion awards.
Now, according to the blog IP Finance, the Japanese are going to try a similar fund in life sciences. We will have to wait and see if they are any more successful.
Leave a comment